UCB Modeling Itself After Genentech As Next-Generation Biopharma Firm
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
UCB’s imminent submission of Cimzia for rheumatoid arthritis slated for the end of the year is another step toward a stronger biotech presence for the company.